J F Colombel

Summary

Affiliation: CHRU de Lille
Country: France

Publications

  1. ncbi request reprint Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults
    Jean Frederic Colombel
    Hopital Huriez, Service d Hepatogastroenterologie, CHU Lille, rue Polonovski, 59037 Lille, Cedex, France
    Expert Rev Gastroenterol Hepatol 2:163-76. 2008
  2. ncbi request reprint The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice?
    Jean Frederic Colombel
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CHRU de Lille and Registre EPIMAD, Hopital Calmette, Lille, France
    Clin Gastroenterol Hepatol 1:5-9. 2003
  3. pmc Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
    J F Colombel
    Gastroenterology Unit, Hopital Claude Huriez, Lille, France
    Gut 49:42-6. 2001
  4. doi request reprint Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Am J Gastroenterol 104:1170-9. 2009
  5. doi request reprint Infliximab, azathioprine, or combination therapy for Crohn's disease
    Jean Frederic Colombel
    Hôpital Claude Huriez and Centre d Investigation Clinique, Centre Hospitalier Universitaire de Lille, Universite Lille Nord de France, Lille, France
    N Engl J Med 362:1383-95. 2010
  6. ncbi request reprint [Inflammatory bowel diseases: a disease of the century]
    Jean Frederic Colombel
    Service d hépato gastro entérologie et Inserm EPI 01 14, Hopital Claude Huriez, 59037 Lille
    Rev Prat 55:941-2. 2005
  7. ncbi request reprint Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
    J F Colombel
    Service d Hepato Gastroenterologie, Hopital Huriez, CHRU Lille, France
    Gastroenterology 118:1025-30. 2000
  8. ncbi request reprint Natalizumab: a promising treatment for Crohn's disease
    Jean Frederic Colombel
    Hopital Huriez, Service d Hépato Gastro Entérologie Rue Polonovski 59037 Lille Cedex, France
    Expert Rev Clin Immunol 2:677-89. 2006
  9. ncbi request reprint Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
  10. pmc Adalimumab for the treatment of fistulas in patients with Crohn's disease
    J F Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France
    Gut 58:940-8. 2009

Detail Information

Publications34

  1. ncbi request reprint Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults
    Jean Frederic Colombel
    Hopital Huriez, Service d Hepatogastroenterologie, CHU Lille, rue Polonovski, 59037 Lille, Cedex, France
    Expert Rev Gastroenterol Hepatol 2:163-76. 2008
    ..This article reviews the efficacy and safety of adalimumab in the treatment of adult patients with CD and discusses the role of adalimumab in the current and future management of CD...
  2. ncbi request reprint The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice?
    Jean Frederic Colombel
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CHRU de Lille and Registre EPIMAD, Hopital Calmette, Lille, France
    Clin Gastroenterol Hepatol 1:5-9. 2003
  3. pmc Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
    J F Colombel
    Gastroenterology Unit, Hopital Claude Huriez, Lille, France
    Gut 49:42-6. 2001
    ..We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery...
  4. doi request reprint Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Am J Gastroenterol 104:1170-9. 2009
    ....
  5. doi request reprint Infliximab, azathioprine, or combination therapy for Crohn's disease
    Jean Frederic Colombel
    Hôpital Claude Huriez and Centre d Investigation Clinique, Centre Hospitalier Universitaire de Lille, Universite Lille Nord de France, Lille, France
    N Engl J Med 362:1383-95. 2010
    ..The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown...
  6. ncbi request reprint [Inflammatory bowel diseases: a disease of the century]
    Jean Frederic Colombel
    Service d hépato gastro entérologie et Inserm EPI 01 14, Hopital Claude Huriez, 59037 Lille
    Rev Prat 55:941-2. 2005
  7. ncbi request reprint Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
    J F Colombel
    Service d Hepato Gastroenterologie, Hopital Huriez, CHRU Lille, France
    Gastroenterology 118:1025-30. 2000
    ..We investigated the distribution of mutant alleles associated with TPMT deficiency in patients with CD and myelosuppression during azathioprine/6-mercaptopurine therapy...
  8. ncbi request reprint Natalizumab: a promising treatment for Crohn's disease
    Jean Frederic Colombel
    Hopital Huriez, Service d Hépato Gastro Entérologie Rue Polonovski 59037 Lille Cedex, France
    Expert Rev Clin Immunol 2:677-89. 2006
    ..This article reviews the properties of natalizumab and addresses its potential benefits and risks in the treatment of CD...
  9. ncbi request reprint Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
    ....
  10. pmc Adalimumab for the treatment of fistulas in patients with Crohn's disease
    J F Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France
    Gut 58:940-8. 2009
    ..To evaluate the efficacy of adalimumab in the healing of draining fistulas in patients with active Crohn's disease (CD)...
  11. ncbi request reprint Adalimumab safety in global clinical trials of patients with Crohn's disease
    Jean Frederic Colombel
    Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    Inflamm Bowel Dis 15:1308-19. 2009
    ....
  12. ncbi request reprint Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions
    C Duburque
    Department of Hepato Gastroenterology, CHRU of Lille, Lille Cedex, France
    Aliment Pharmacol Ther 24:851-8. 2006
    ..To appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment...
  13. pmc Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease
    B Meresse
    Equipe Propre Institut National de la Santé et de la Recherche Médical 0114 sur la Physiopathologie des Maladies Inflammatoires Intestinales, CHU Lille, France
    Gut 50:25-8. 2002
    ..Abnormal intestinal production of pro- (interleukin (IL)-1 beta, tumour necrosis factor alpha (TNF-alpha)) and anti- (IL-10) inflammatory cytokines has been associated with severe outcome in experimental models of colitis...
  14. pmc Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
    A Cortot
    Service de Gastroenterologie, Hopital Claude Huriez, Lille, France
    Gut 48:186-90. 2001
    ..Steroid dependent patients with Crohn's disease are at high risk of developing glucocorticosteroid induced side effects...
  15. pmc Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study
    S Baron
    Registre des Maladies Inflammatoires Chroniques de l Intestin EPIMAD, Service d Epidémiologie et de Santé Publique, Hopital Calmette, Lille, France
    Gut 54:357-63. 2005
    ..Environmental exposures in early life have been implicated in the aetiology of inflammatory bowel disease...
  16. pmc Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation
    D Philippe
    INSERM, Lille, France
    Gut 55:815-23. 2006
    ....
  17. ncbi request reprint CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease
    B Meresse
    Service d'Immunologie, EA 2686, Lille, France
    Hum Immunol 62:694-700. 2001
    ..Such perturbation of the IEL population within the ileal mucosa could contribute to the inflammation in Crohn disease...
  18. pmc Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein
    G Torpier
    Unité Mixte INSERM U 167 CNRS 624, Institut Pasteur, Lille, France
    Clin Exp Immunol 74:404-8. 1988
    ..The diffusion of one granule protein from the granules to the exterior of the cells favours the view of a selective release of eosinophil mediators...
  19. pmc Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis
    P Desreumaux
    Clinique des Maladies de l Appareil Digestif, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire CHRU, Lille, France
    Gut 37:132-5. 1995
    ..It is suggested that duodenal and cutaneous eosinophils can synthesise IL5 and then participate in small bowel and skin lesions...
  20. pmc Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine
    G Vernier-Massouille
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CH et U de Lille, France
    Gut 56:1404-9. 2007
    ....
  21. ncbi request reprint Early vascular changes in Crohn's disease: an endoscopic fluorescence study
    V Maunoury
    Dept of Gastroenterology, University Hospital, Lille, France
    Endoscopy 32:700-5. 2000
    ..The aim of this study was use fluorescence endoscopy to evaluate the mucosal microcirculation of the neoterminal ileum in relation to endoscopic recurrence in patients who had undergone ileocolonic resection for Crohn's disease...
  22. doi request reprint Pre-operative management is associated with low rate of post-operative morbidity in penetrating Crohn's disease
    P Zerbib
    Department of Digestive Surgery and Transplantation, Univ Lille Nord de France, CHU Lille, France
    Aliment Pharmacol Ther 32:459-65. 2010
    ..Ileocaecal resection for penetrating Crohn's disease is still challenging with a high rate of post-operative morbidity and faecal diversion...
  23. ncbi request reprint [Desensitisation to infliximab in patients with Crohn's disease]
    J Lelong
    Service de pneumo allergologie, Clinique des Maladies Respiratoires, Hopital Albert Calmette, CHRU, Lille, France
    Rev Mal Respir 22:239-46. 2005
    ..Infliximab infusions have been associated both with immediate and delayed reactions...
  24. ncbi request reprint Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases
    A Guidat
    Hopital Claude Huriez, Département d Anesthésie Réanimation 2, Lille, France
    Eur J Anaesthesiol 20:957-62. 2003
    ..Sufentanil requirements were assessed during surgery...
  25. ncbi request reprint [Infliximab therapy for Crohn's disease anoperineal lesions]
    A Ouraghi
    , CHU, Lille, France
    Gastroenterol Clin Biol 25:949-56. 2001
    ..CONCLUSION: Remicade is rapidly effective and well tolerated in anoperineal Crohn's lesions, but the high relapse rate stresses the need for long term therapeutic strategies in these patients...
  26. pmc Mucin gene expression in intestinal epithelial cells in Crohn's disease
    M P Buisine
    Unité Inserm no 377, Lille, France
    Gut 49:544-51. 2001
    ..Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease of unknown origin. It is characterised by chronic mucosal ulcerations which affect any part of the intestine but most commonly are found in the ileum and proximal colon...
  27. pmc Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
    P Desreumaux
    Equipe Propre Institut National de la Sante et de la Recherche Medicale 0114 sur la Physiopathologie des Maladies Inflammatoires Intestinales, CHU Lille 59037, France
    J Exp Med 193:827-38. 2001
    ....
  28. pmc Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999)
    F Molinie
    Registre des Maladies Inflammatoires Chroniques de l Intestin EPIMAD, Service d Epidémiologie et de Santé Publique, Hopital Calmette, CHR and U de Lille, 59037 Lille Cedex, France
    Gut 53:843-8. 2004
    ..Northern France was characterised by a high incidence of Crohn's disease (CD) and a low incidence of ulcerative colitis (UC) according to the first inquiry undertaken in the late 1980s...
  29. ncbi request reprint Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients
    F Blondel-Kucharski
    , CHU, Lille, France
    Am J Gastroenterol 96:2915-20. 2001
    ..CONCLUSION: Patients' QoL is impaired by CD and is underestimated by doctors. Tobacco, hospitalization, and use of corticoids have a negative impact on QoL. Conversely, the use of immunosuppressors is associated with a better QoL...
  30. ncbi request reprint Qualitative study of fecal alpha 1-proteinase inhibitor in normal subjects and patients with Crohn's disease
    C Mizon
    Laboratoire de Biochimie, , Lille, France
    Clin Chem 34:2268-70. 1988
    ..In contrast, alpha 1 PI of Mr 51,000 was detected in fecal extracts from eight patients with active Crohn's disease (CDAI = 287, SEM 39). We conclude that fecal alpha 1 PI can be considered a marker of intestinal disease activity...
  31. doi request reprint Systematic review: fertility in non-surgically treated inflammatory bowel disease
    N Tavernier
    Department of Hepato Gastroenterology, University Lille Nord de France, CHRU Lille, Lille, France
    Aliment Pharmacol Ther 38:847-53. 2013
    ..Inflammatory bowel diseases (IBD) typically affect young patients during the reproductive years, and reproductive issues are of key concern to them...
  32. pmc Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan
    B Sendid
    INSERM U799, Universite Lille 2, Lille, France
    Clin Vaccine Immunol 15:1868-77. 2008
    ..Future trials are necessary to assess the value of these tests in multiparametric analysis, as well as their pathophysiological relevance...
  33. ncbi request reprint Simple gas chromatography analysis of faecal butyrate: application to patients at risk of pouchitis
    G Renom
    Laboratoire de Biochimie, Hopital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France
    Clin Chem Lab Med 39:15-9. 2001
    ..We also observed a noticeable reduction in the concentration of butyrate in patients who went on to develop a pouchitis...
  34. ncbi request reprint Alpha-chain disease: analysis of alpha-chain protein and secretory component in jejunal fluid
    D Lucidarme
    Laboratoire d Explorations Fonctionelles Digestives, Centre Hospitalier Regional Universitaire, Lille, France
    Gastroenterology 104:278-85. 1993
    ..This was studied in a 23-year-old Mauritanian man in whom alpha-chain disease was diagnosed localized to the duodenum and jejunum, nasopharynx, and bone marrow...